Search

Aim Retrospective analysis of disease clinical course with a purpose of defining potential prognostic parameters which are essential for optimal target therapy. Methods The study involved 29 patients with histologically confirmed lung adenocarcinoma and existing epidermal growth factor receptor (EGFR) mutations, which are treated by tyrosine kinase inhibitors (TKI). Results Allegations of a larger prevalence in women and non-smokers were found. The study confirmed dominance of mutations on exon 19 and exon 21. Usefulness of the treatment with erlotinib in terms of increasing survival time was evident. Median survival of patients in the survey sample was 14.5 months. Median survival in relation to gender or smoking status did not show statistical significance. Conclusion Considering obtained results, we have confirmed that patients with advanced lung adenocarcinoma and present mutations of epidermal growth factor receptor, who had been treated with first generation TKI, had median survival time of over a year.